ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023
SHENZHEN, China, June 6, 2023 /PRNewswire/ — ImmVira submitted four abstracts covering latest results from Phase I/II clinical trials of MVR-T3011 IT (intratumoral injection) and MVR-T3011 IV (intravenous injection) in both U.S. and China with all selected to be published (1 chosen for poster discussion) at the 2023 American Society for Clinical Oncology Annual Meeting (ASCO … Read more